Healthcare

Control Bionics Limited (ASX:CBL) is a neurotechnology medical device company whose products include the NeuroNode wearable sensor and related assistive technology. The company held itsAnnual General Meetingon Tuesday, 13 October 2026 and released the results of the meeting the same day, in accordance with …

InteliCare Holdings Limited (ASX:ICR) is an Australian healthcare technology company developing artificial intelligence-powered monitoring and predictive analytics solutions for aged care providers and people requiring additional support.

Alcidion currently has approximately 1.35 billion ordinary shares and approximately 26.7 million performance rights on issue. Following the consolidation, it expects to have approximately 135 million ordinary shares and approximately 2.7 million performance rights.

Cash and term deposits at 30 September 2026 were A$20.9 million, made up of A$7.9 million in cash and A$13.0 million in term deposits. Net operating cash outflow was A$1.0 million, compared with A$3.4 million in Q4 FY2026 (A$2.6 million excluding one-off redundancy payments) …

Following discussions with Obsidian, the parties agreed to redeem and cancel a further 1,171,477 convertible notes for a cash payment of US$1,404,600, approximately A$2 million. The notes were redeemed and cancelled on completion of payment, leaving 3,125,708 convertible notes outstanding.

GroupRevenueincreased 22% to US$477 million in H1 2026 from US$390 million in the prior corresponding period.

Mesoblast (ASX:MSB) carries a consensus analyst rating of Buy. Of the 6 analyst recommendations recorded, 6 are Buy or equivalent, 0 are Hold and 0 are Sell or equivalent. The mean price target is A$3.64, with targets ranging from A$2.90 to A$4.45, against a …